drugset / Trial / NCT01397461

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT01397461

Phase 3 Completed 465 enrolled Ferrer Internacional S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study comparing ozenoxacin cream versus placebo and retapamulin ointment vs placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.

Timeline

Start
2012-03
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozenoxacin Other / unclassified 1 % Topical
Comparator Retapamulin Small molecule 1 % Topical

Indications